Cargando…

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9 levels would be associated with death and ICU ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Metkus, Thomas S., Kim, Bo Soo, Jones, Steven R., Martin, Seth S., Schulman, Steven P., Leucker, Thorsten M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234242/
https://www.ncbi.nlm.nih.gov/pubmed/35770004
http://dx.doi.org/10.3389/fmed.2022.876046
_version_ 1784736023538827264
author Metkus, Thomas S.
Kim, Bo Soo
Jones, Steven R.
Martin, Seth S.
Schulman, Steven P.
Leucker, Thorsten M.
author_facet Metkus, Thomas S.
Kim, Bo Soo
Jones, Steven R.
Martin, Seth S.
Schulman, Steven P.
Leucker, Thorsten M.
author_sort Metkus, Thomas S.
collection PubMed
description BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9 levels would be associated with death and ICU outcomes in patients with ARDS. METHODS: Using data and plasma samples from the NIH BioLINCC data repository, we assembled a cohort of 1,577 patients with the acute respiratory distress syndrome (ARDS) enrolled in two previously completed clinical trials, EDEN and SAILS. We measured PCSK9 levels in plasma within 24 h of intubation using commercially available ELISA kits (R&D Systems). We assessed the association of PCSK9 with mortality using Cox proportional hazard models. We also assessed clinical factors associated with PCSK9 level and the association of PCSK9 with the number of days free of mechanical ventilation and days free of ICU care. RESULTS: In 1,577 ARDS patients, median age was 53 years (IQR 42–65 years) and median APACHE III score 91 (72–111) connoting moderate critical illness. PCSK9 levels were 339.3 ng/mL (IQR 248.0–481.0). In multivariable models, race, cause of ARDS, body mass index, pre-existing liver disease, body temperature, sodium, white blood cell count and platelet count were associated with PCSK9 level. Presence of sepsis, use of vasopressors and ventilator parameters were not associated with PCSK9 level. PCSK9 levels were not associated with in-hospital mortality (HR per IQR 0.96, 95% CI 0.84–1.08, P = 0.47). Higher PCSK9 levels were associated with fewer ICU and ventilator free days. CONCLUSIONS: Plasma PCSK9 is not associated with mortality in ARDS, however higher PCSK9 levels are associated with secondary outcomes of fewer ICU free and ventilator free days. Clinical factors associated with PCSK9 in ARDS are largely unmodifiable. Further research to define the mechanism of this association is warranted.
format Online
Article
Text
id pubmed-9234242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92342422022-06-28 Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome Metkus, Thomas S. Kim, Bo Soo Jones, Steven R. Martin, Seth S. Schulman, Steven P. Leucker, Thorsten M. Front Med (Lausanne) Medicine BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9 levels would be associated with death and ICU outcomes in patients with ARDS. METHODS: Using data and plasma samples from the NIH BioLINCC data repository, we assembled a cohort of 1,577 patients with the acute respiratory distress syndrome (ARDS) enrolled in two previously completed clinical trials, EDEN and SAILS. We measured PCSK9 levels in plasma within 24 h of intubation using commercially available ELISA kits (R&D Systems). We assessed the association of PCSK9 with mortality using Cox proportional hazard models. We also assessed clinical factors associated with PCSK9 level and the association of PCSK9 with the number of days free of mechanical ventilation and days free of ICU care. RESULTS: In 1,577 ARDS patients, median age was 53 years (IQR 42–65 years) and median APACHE III score 91 (72–111) connoting moderate critical illness. PCSK9 levels were 339.3 ng/mL (IQR 248.0–481.0). In multivariable models, race, cause of ARDS, body mass index, pre-existing liver disease, body temperature, sodium, white blood cell count and platelet count were associated with PCSK9 level. Presence of sepsis, use of vasopressors and ventilator parameters were not associated with PCSK9 level. PCSK9 levels were not associated with in-hospital mortality (HR per IQR 0.96, 95% CI 0.84–1.08, P = 0.47). Higher PCSK9 levels were associated with fewer ICU and ventilator free days. CONCLUSIONS: Plasma PCSK9 is not associated with mortality in ARDS, however higher PCSK9 levels are associated with secondary outcomes of fewer ICU free and ventilator free days. Clinical factors associated with PCSK9 in ARDS are largely unmodifiable. Further research to define the mechanism of this association is warranted. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234242/ /pubmed/35770004 http://dx.doi.org/10.3389/fmed.2022.876046 Text en Copyright © 2022 Metkus, Kim, Jones, Martin, Schulman and Leucker. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Metkus, Thomas S.
Kim, Bo Soo
Jones, Steven R.
Martin, Seth S.
Schulman, Steven P.
Leucker, Thorsten M.
Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
title Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
title_full Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
title_fullStr Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
title_full_unstemmed Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
title_short Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
title_sort plasma proprotein convertase subtilisin/kexin type 9 (pcsk9) in the acute respiratory distress syndrome
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234242/
https://www.ncbi.nlm.nih.gov/pubmed/35770004
http://dx.doi.org/10.3389/fmed.2022.876046
work_keys_str_mv AT metkusthomass plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome
AT kimbosoo plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome
AT jonesstevenr plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome
AT martinseths plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome
AT schulmanstevenp plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome
AT leuckerthorstenm plasmaproproteinconvertasesubtilisinkexintype9pcsk9intheacuterespiratorydistresssyndrome